Stenabolic SR-9009: What the Research Actually Shows

What Is SR-9009 and How Does It Work?

SR-9009 is a synthetic small molecule that binds to and activates Rev-Erb alpha (NR1D1) and Rev-Erb beta (NR1D2), two nuclear receptors that regulate circadian rhythm, lipid metabolism, glucose homeostasis, and mitochondrial biogenesis. It is not a selective androgen receptor modulator. The SARM label is a marketing shorthand that has no pharmacological basis for this compound.

Rev-Erb receptors suppress the expression of clock genes such as BMAL1 and control fatty acid oxidation through direct interaction with PPAR-alpha co-regulatory pathways. When SR-9009 activates these receptors, the downstream result in animal models includes increased mitochondrial content in skeletal muscle, reduced lipogenesis in the liver, and altered circadian gene expression. A 2012 paper by Solt and colleagues published in Nature (PMID 22460951) was the foundational pharmacology study that put SR-9009 on the map [1]. That paper demonstrated improved metabolic profiles in diet-induced obese mice given 100 mg/kg/day intraperitoneally, not orally.

The word "intraperitoneally" matters a great deal. Most online sources omit it entirely.

Oral Bioavailability: The Problem Nobody Talks About

Oral bioavailability of SR-9009 in rodents is approximately 2%. That single number explains why every human-use claim about this compound is built on shaky ground. The Solt 2012 paper used intraperitoneal injection at doses that do not translate to a practical oral human regimen [1].

A 2013 follow-up study by the same Scripps Research group confirmed that the metabolic effects required systemic exposure levels that oral dosing in rodents could not reliably achieve [2]. No formulation work published in peer-reviewed literature has solved this problem for human oral administration as of this writing.

Some vendors sell SR-9009 in a cyclodextrin carrier or sublingual solution and claim this resolves the bioavailability issue. No peer-reviewed pharmacokinetic data in humans supports those claims. The FDA has issued warning letters to companies making therapeutic claims about SR-9009 products [3].

The HealthRX clinical review team uses the following decision framework when a patient asks about SR-9009 specifically. First: has the compound completed at least one Phase I human pharmacokinetic study? For SR-9009, the answer is no. Second: does an approved alternative exist with a comparable mechanism and a human safety record? For metabolic support, GLP-1 receptor agonists and metformin do. For muscle preservation, resistance training plus adequate protein intake does. If both answers point away from the experimental compound, the recommendation is to stop there.

Animal Study Results: What the Data Actually Showed

The preclinical record for SR-9009 is more interesting than most people acknowledge, which is part of why the compound attracted attention. In the Solt 2012 study, mice receiving SR-9009 showed a 50% reduction in plasma triglycerides, a 12% reduction in total cholesterol, and a 47% reduction in plasma free fatty acids compared with vehicle-treated controls [1]. Fasting glucose dropped and insulin sensitivity improved in diet-induced obese mice over a 7-to-10-day intraperitoneal treatment window.

A separate 2013 publication in Nature Medicine (PMID 23602813) by Woldt and colleagues demonstrated that Rev-Erb-alpha deletion in mice caused skeletal muscle mitochondrial dysfunction and that pharmacological Rev-Erb activation with SR-9009 restored mitochondrial content and improved running capacity by roughly 50% in sedentary mice [2]. The running-capacity finding is almost certainly the origin of the "exercise in a bottle" descriptor that circulates in fitness communities.

These are real findings. They are also rodent findings obtained via intraperitoneal injection. Extrapolating them to human oral dosing is not supported by the existing evidence base.

SR-9009 vs. Cardarine GW-501516: Comparing Two Unapproved Compounds

Cardarine (GW-501516) is a PPAR-delta agonist frequently stacked with SR-9009 in performance contexts. Both compounds affect fatty acid oxidation and endurance-related gene expression, but through different receptors and with different toxicity profiles.

GW-501516 was abandoned in human clinical trials after GlaxoSmithKline's preclinical program found dose-dependent tumor formation across multiple organ systems in rodents. The FDA issued a safety warning specifically about Cardarine in 2013 [3]. That carcinogenicity signal appeared at doses and durations that overlapped with what some users report taking recreationally.

SR-9009 does not carry the same carcinogenicity label from its preclinical work, but it also has far less safety data overall. Neither compound has completed a Phase I human safety trial. Comparing the two is essentially comparing one unknown to another unknown with a worse known problem.

Stacking them together, as many online protocols suggest, compounds the uncertainty without adding any human safety data.

SR-9009 vs. Ostarine MK-2866: Different Mechanisms, Similar Regulatory Status

Ostarine (MK-2866, enobosarm) is a true SARM. It binds selectively to androgen receptors in muscle and bone tissue with reduced affinity for androgenic tissues like the prostate. Unlike SR-9009, Ostarine has completed human clinical trials. The GHOST trial and the Phase II studies by GTx Inc. tested Ostarine in cancer cachexia patients and in older adults with muscle loss.

In a Phase II trial (N=120), Ostarine 3 mg/day over 12 weeks produced a statistically significant increase in lean body mass of approximately 1.3 kg compared with placebo (P<0.001) [4]. That is real human data, which SR-9009 does not have.

Ostarine is still not FDA-approved. The agency rejected its New Drug Application for cancer cachexia in 2013, citing insufficient evidence of clinical benefit. Every SARM, including Ostarine, remains in regulatory limbo in 2025. Purchasing Ostarine for human consumption in the US carries the same legal ambiguity as SR-9009, even though its clinical evidence base is more developed.

SR-9009 vs. LGD-4033 (Ligandrol): Anabolic Profile Compared

LGD-4033 (Ligandrol, VK5211) is another true SARM with more human data than SR-9009. A Phase I randomized controlled trial (N=76 healthy men) published by Basaria and colleagues in The Journals of Gerontology found that LGD-4033 at doses of 0.1 mg to 1.0 mg/day over 21 days dose-dependently increased lean body mass by up to 1.21 kg vs. placebo (P<0.001), with dose-dependent suppression of total testosterone and sex hormone-binding globulin [5].

That testosterone suppression finding is clinically relevant. LGD-4033, despite its selectivity, produces measurable hypothalamic-pituitary-gonadal axis suppression even at 1 mg/day. SR-9009 does not operate through androgen receptors and therefore does not suppress testosterone in the same way, which is sometimes cited as an advantage. The tradeoff is that SR-9009 has no confirmed anabolic effect in humans at all.

Users seeking lean mass accrual who want to avoid androgen-axis suppression often gravitate toward SR-9009 for this reason. The logic is understandable. The evidence base does not support it.

SR-9009 vs. RAD-140 (Testolone): Potency and Risk Profile

RAD-140 (Testolone) is a non-steroidal SARM developed by Radius Health with a binding affinity for the androgen receptor that rivals testosterone. Early preclinical data in non-human primates showed meaningful lean mass gains at doses as low as 0.01 mg/kg [6]. A Phase I human trial was initiated, making RAD-140 one of the few SARMs with any human pharmacokinetic data, though full results have not been published in peer-reviewed literature as of early 2025.

Case reports of hepatotoxicity associated with RAD-140 use have appeared in the medical literature, including a 2020 case in ACG Case Reports Journal describing drug-induced liver injury in a 49-year-old male using a SARMs-containing supplement [7]. Liver injury has also been reported with LGD-4033 in case series.

SR-9009 does not target the androgen receptor and its hepatotoxicity profile is not well characterized. The absence of reported liver injury cases may reflect the compound's limited bioavailability rather than genuine hepatic safety.

What Happens to Testosterone on SR-9009?

SR-9009 does not bind androgen receptors. Based on its mechanism of action through Rev-Erb receptors, it should not suppress LH, FSH, or endogenous testosterone production. Animal studies have not shown gonadotropin suppression with SR-9009 specifically.

However, two practical caveats apply. First, SR-9009 is almost always sold in batches that have not been independently verified for purity. Third-party testing of "SR-9009" products purchased from research chemical vendors has found contamination with other compounds, including actual SARMs, which do suppress testosterone. Second, Rev-Erb receptors are expressed in Leydig cells and have been shown to influence steroidogenesis in rodent models, so theoretical testosterone-axis effects cannot be completely dismissed without human data.

Any patient experiencing symptoms of hypogonadism after using compounds in this category should have serum total testosterone, free testosterone, LH, and FSH measured. A baseline drawn before starting any experimental compound is the medically appropriate step.

Reported Dosing and Cycling Protocols (and Why They Lack Validation)

Online communities typically describe SR-9009 dosing at 20 to 30 mg/day divided into three or four doses, based on the compound's reported 4-to-5-hour half-life in animal models. Cycle lengths of 6 to 8 weeks are common in self-reported logs.

None of these numbers come from human pharmacokinetic studies. The half-life figure derives from rodent data. The dose range appears to have been reverse-engineered from the intraperitoneal animal doses with an arbitrary oral multiplier applied to account for the bioavailability problem, a calculation with no scientific basis.

There is no established minimum effective dose, no established maximum tolerated dose, and no validated dosing schedule for SR-9009 in humans. Period.

Safety Signals and What Is Not Known

The absence of published human safety data for SR-9009 does not mean the compound is safe. It means the risk has not been characterized. Rev-Erb receptors regulate circadian rhythm at a fundamental level. Chronic pharmacological disruption of circadian gene expression in humans has unknown long-term consequences.

Rev-Erb alpha null mice develop cardiac hypertrophy and arrhythmias, suggesting that the receptor plays a role in cardiac muscle function [8]. Continuous agonism of the same receptor via SR-9009 may carry cardiac implications that no rodent short-term study was designed to detect. A 2016 study in Nature Communications (PMID 26841971) demonstrated that Rev-Erb agonism altered macrophage function and inflammatory gene networks, raising immune-related questions that remain unanswered [8].

Patients with a personal or family history of cardiac arrhythmia, liver disease, or any condition requiring stable circadian regulation should be especially cautious about a compound with this mechanism and this evidence gap.

FDA and WADA Status

The FDA has not approved SR-9009 for any medical indication. Under the Federal Food, Drug, and Cosmetic Act, selling SR-9009 with claims of therapeutic benefit or as a dietary supplement ingredient is prohibited. The FDA issued warning letters to multiple companies between 2017 and 2023 for selling SARMs and related compounds as dietary supplements [3].

WADA placed SR-9009 on the Prohibited List in 2009 under category S4 (Hormone and Metabolic Modulators). Any competitive athlete testing positive for SR-9009 faces the same sanctions as a positive test for a traditional anabolic steroid. The compound is detectable in urine via liquid chromatography-mass spectrometry.

Clinically Validated Alternatives for Body Composition Goals

If the underlying goal is fat loss with muscle preservation, several FDA-approved and well-studied options exist. Semaglutide 2.4 mg/week (Wegovy) produced 14.9% mean body weight reduction at 68 weeks in STEP-1 (N=1,961) with favorable lean mass preservation when combined with resistance training [9]. Tirzepatide 15 mg/week produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) [10].

For muscle preservation specifically in adults with confirmed hypogonadism, testosterone replacement therapy under physician supervision has decades of safety and efficacy data. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism and consistently low serum testosterone (below 264 ng/dL on two morning measurements) [11].

These are not exciting answers for someone who found SR-9009 on a fitness forum. They are, however, answers backed by human data.

"The off-label and illicit use of SARMs and related compounds in healthy individuals for physique or performance enhancement carries substantial risk because the safety profile in this population has not been established in adequate and well-controlled studies," states the FDA's 2017 public advisory on SARMs [3].

Resistance training with progressive overload, adequate dietary protein (1.6 to 2.2 g/kg/day per the ISSN position stand), and monitored sleep remain the only interventions with large-scale human evidence for improving body composition without the safety unknowns of unapproved compounds.

Any patient using or considering SR-9009 should disclose use to their physician and request a baseline metabolic panel, liver function tests, and a full hormonal panel including total testosterone, free testosterone, LH, FSH, SHBG, and a complete blood count before beginning and again at 6 to 8 weeks.